BOOSTRIX Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed 5 [iU]/.5mL; 2.5 [iU]/.5mL; 8 ug/.5mL Suspension, 10 syringes — NDC 50090-1377-0 (Billing 50090-1377-00)
This is a package of 10 syringes of BOOSTRIX Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed 5 [iU]/.5mL; 2.5 [iU]/.5mL; 8 ug/.5mL Suspension from A-S Medication Solutions, marketed since Jul 2009 and currently FDA-listed. It is the main listing for this product, which comes in 2 package sizes.
NDC database record
One package, one record: these facts belong to NDC 50090-1377-0 alone.
- Record
- FDA NDC Directory package listing · Vaccine
- Code segments
- 50090 labeler · 1377 product · 0 package
- Package marketed since
- Jul 24, 2009
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Barcode (UPC-A, from the NDC)
- 3 5009013770 5
- FDA record last changed
- Oct 8, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 059080
- GCN: 24619
- GPI-14 (Medi-Span): 1899000322E620
- HICL (First Databank): 006320
- AHFS class code: 80:08.00.00
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 8, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 8, 2026
Clinical
Why get vaccinated? Diphtheria, tetanus, and pertussis (DTaP) vaccine may prevent diphtheria, tetanus, and pertussis that may occur with infection due to C. diphtheriae (diphtheria), C. tetani (tetanus), and B. pertussis (pertussis). Infection with C. diphtheriae can cause diphtheria (difficulty breathing and life-threatening heart failure and paralysis), infection with C. tetani can cause tetanus (painful stiffening of the muscles), and infection with B. pertussis can cause whooping cough (a respiratory disease with severe coughing episodes). Diphtheria, tetanus, and pertussis (DTaP) vaccin...
Read the full MedlinePlus article ↗Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 8, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
| Medicare Part B allowsASP · 90715 | $40.290 / 90715 unit | — |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 8, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Billing & reimbursement
Where does this data come from?
- CMS ASP NDC-HCPCS crosswalk · refreshed Sep 22, 2026
- DMEPDAC NDC-HCPCS crosswalk
- openFDA NSDE billing units · refreshed Oct 7, 2026
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 50090-1377-00 You're viewing this Main listing | 10 SYRINGE in 1 CARTON / .5 mL in 1 SYRINGE | 2009-07-24 | — | Active |
| 50090-1377-01 50090-1377-1 | 1 SYRINGE in 1 POUCH / .5 mL in 1 SYRINGE | 2009-07-24 | — | Active |
Pack size FAQ
What quantity is in this package?
How does this package differ from NDC 50090-1377-01?
What NDC number is used to bill for this package of BOOSTRIX Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed 5 [iU]/.5mL; 2.5 [iU]/.5mL; 8 ug/.5mL Suspension?
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Boostrix 5 [iU]/.5mL; 2.5 [iU]/.5mL; 8 ug/.5mLthis 50090-1377-00 | A-S | 10 syringes | — | — | FDA listed | — |
| Boostrix 5 [iU]/.5mL; 2.5 [iU]/.5mL; 8 ug/.5mL 58160-0842-11 | GlaxoSmithKline | 10 vials | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA Purple Book · refreshed Oct 5, 2026
- CMS NADAC weekly file
Availability & biosimilar status
Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.
Where does this data come from?
- FDA Purple Book · refreshed Oct 5, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.- FDA label on DailyMed · label index refreshed Oct 8, 2026
- FDA openFDA NDC Directory · synced Oct 8, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from A-S Medication Solutions labeler code 50090
- Flumazenil .1 mg/mL Injection, Solution NDC 50090-1337-0
- Mucinex Guaifenesin 600 mg Tablet, Extended Release NDC 50090-1340-0
- Amoxicillin 400 mg/5mL Powder, For Suspension NDC 50090-1347-0
- NEW TEROCIN Methyl Salicylate, Capsaicin, and Menthol 25 g/100mL; .025 g/100mL; 10 g/100mL Lotion NDC 50090-1353-0
- Lidocaine 50 mg/g Patch NDC 50090-1359-2
- HUMALOG Insulin lispro 100 [iU]/mL Injection, Solution NDC 50090-1375-0
- IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE 2.5 mg/3mL; .5 mg/3mL Solution NDC 50090-1382-0
- VIORELE Desogestrel and Ethinyl Estradiol Kit NDC 50090-1395-0
- Lantus Solostar insulin glargine 100 [iU]/mL Injection, Solution NDC 50090-1398-0
- verapamil hydrochloride 120 mg Tablet, Film Coated, Extended Release NDC 50090-1400-0
- SYMBICORT Budesonide and Formoterol Fumarate Dihydrate 160 ug; 4.5 ug Aerosol NDC 50090-1403-0
- Amlodipine and Benazepril Hydrochloride 10 mg; 20 mg Capsule NDC 50090-1418-0
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- Drugs@FDA
Full FDA label FDA SPL
📄 FDA label ▾
No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | — Not published for this NDC No photo available yet for this listing. |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | ✓ Available |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |